Discover investment opportunities in Penny Stocks To Buy 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Penny Stocks To Buy 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Penny Stocks To Buy 2024 using our Smart AI Filter.
6 stocks found for "Penny Stocks To Buy 2024"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.90 Risk measure | ±50.6% Price volatility | 161.0 Valuation | 0.00% Annual yield | |||
0.70 Risk measure | ±100.0% Price volatility | 11.6 Valuation | 0.00% Annual yield | |||
0.86 Risk measure | ±55.0% Price volatility | 41.8 Valuation | 0.00% Annual yield | |||
1.41 Risk measure | ±67.6% Price volatility | -20.4 Valuation | 0.00% Annual yield | |||
0.77 Risk measure | ±68.2% Price volatility | -1.5 Valuation | 0.00% Annual yield | |||
2.07 Risk measure | ±100.0% Price volatility | -4.2 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreCannabis grower Organigram Holdings Inc OGI reported second-quarter 2025 net sales of $45.7 million (approximately CA$65.6 million). That's up 74% year-over-year, beating the consensus of $42.28 million.
Read moreSNDL Inc. (SNDL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.01 per share a year ago.
Read moreVistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
Read moreThe heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreNano Dimension Ltd (NASDAQ: NNDM) reported a fourth-quarter revenue increase of 282% Y/Y to $7.53 million from $1.97 million in 4Q20. The company attributed the revenue surge mainly to the consolidation of Essemtec, which it purchased in November 2021.
Read more